EGFR and breast carcinoma: Bioengineered exosomes with a transmembrane domain fused with the GE11 peptide delivered the let-7a miRNA to EGFR-expressing xenograft breast cancer tissue in immunodeficient mice, leading to an anti-tumor effect [80].